Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 5/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TOP1 | P11387 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5361332 | 0.97 | THRB (0.43) | THRBRXFP1LMNAKDM4EBRD4 | |
| SCHEMBL5461896 | 0.94 | THRB (0.46) | THRBRXFP1LMNAKDM4EBRD4 | |
| SCHEMBL5361869 | 0.93 | LMNA (0.39) | THRBRXFP1LMNAKDM4EBRD4 | |
| SCHEMBL5361098 | 0.90 | LMNA (0.41) | THRBRXFP1LMNAKDM4EBRD4 | |
| SCHEMBL5355775 | 0.89 | THRB (0.45) | THRBRXFP1LMNAKDM4EBRD4 | |
| SCHEMBL5360452 | 0.89 | ALDH1A1 (0.44) | THRBLMNAKDM4EALDH1A1HPGD | |
| SCHEMBL5357545 | 0.88 | THRB (0.43) | THRBRXFP1LMNAKDM4EBRD4 | |
| SCHEMBL5355982 | 0.84 | LMNA (0.43) | LMNAKDM4EALDH1A1HPGDTOP1 | |
| SCHEMBL5354409 | 0.82 | ALDH1A1 (0.43) | THRBLMNAKDM4EALDH1A1HPGD | |
| SCHEMBL5348375 | 0.82 | S1PR1 (0.39) | THRBRXFP1LMNAALDH1A1TOP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070287699-A1 | ANTIVIRAL AGENTS | VIROBAY, INC. (US) | 2007-12-13 | — | — | US | claimed |
| WO-2007130499-A2 | ANTIVIRAL AGENTS | VIROBAY, INC. (US) | 2007-11-15 | — | — | WO | claimed |
| US-20070287699-A1 | ANTIVIRAL AGENTS | VIROBAY, INC. (US) | 2007-12-13 | — | — | US | disclosed |
| US-20070287699-A1 | ANTIVIRAL AGENTS | VIROBAY, INC. (US) | 2007-12-13 | — | — | US | disclosed |
| US-20070287699-A1 | ANTIVIRAL AGENTS | VIROBAY, INC. (US) | 2007-12-13 | — | — | US | disclosed |
| WO-2007130499-A2 | ANTIVIRAL AGENTS | VIROBAY, INC. (US) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287699-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | THRB 4510/4885RXFP1 4526/4885LMNA 4460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.